Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
cAMP-specific 3',5'-cyclic phosphodiesterase 4C (PDE4C) is an enzyme encoded by the PDE4C gene, predominantly expressed in peripheral tissues[3]. It belongs to the cyclic nucleotide phosphodiesterase superfamily and is a member of the PDE4 subfamily. PDE4C hydrolyzes the second messenger cyclic adenosine monophosphate (cAMP), regulating essential signaling pathways that control physiological responses to extracellular stimuli. The enzyme's catalytic domain binds bivalent metal ions (zinc and magnesium), which are crucial for its activity[1]. PDE4C is structurally similar to other PDE4 family members, which are recognized therapeutic targets for treating inflammatory diseases, certain respiratory disorders, and neuropsychiatric conditions. However, PDE4C is less characterized than other family members (such as PDE4D and PDE4B) regarding tissue distribution and disease relevance[2][3].
Inhibition of PDE4C leads to increased intracellular cAMP, which modulates immune and inflammatory responses and other cellular activities
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on cAMP-specific 3',5'-cyclic phosphodiesterase 4C (PDE4C).